Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 71

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016', provides in depth analysis on Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted pipeline therapeutics.

The report provides comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

  • The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Overview 6
Therapeutics Development 7
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Stage of Development 7
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Therapy Area 8
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Indication 9
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Companies 13
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics Development 22
Karyopharm Therapeutics, Inc. 22
Stemline Therapeutics, Inc. 24
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles 25
KPT-251 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
KPT-276 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
KPT-350 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
KPT-8602 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
selinexor - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
SL-801 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
verdinexor - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Projects 51
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products 54
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Featured News & Press Releases 55
Jul 27, 2016: Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting 55
Jul 27, 2016: Karyopharms Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology 56
Jun 16, 2016: Karyopharm Outlines Key Selinexor Clinical Development Achievements 57
Jun 10, 2016: Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting 58
Jun 10, 2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting 59
Jun 06, 2016: Moffitt researchers present phase 1 study results of selinexor combination therapy; multiple myeloma 60
May 19, 2016: Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting 60
May 18, 2016: Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting 61
May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial 63
Apr 20, 2016: Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury 63
Mar 31, 2016: Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus 64
Mar 16, 2016: Karyopharm to Present Data on Oncology drug Selinexor (KPT-330) at the 2016 American Association for Cancer Research Annual Meeting 65
Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-8602 at the 2016 American Association for Cancer Research Annual Meeting 67
Mar 04, 2016: Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology 68
Jan 19, 2016: Karyopharm Initiates Second Generation SINE Compound Clinical Trial in Multiple Myeloma 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 (Contd..1) 15
Products under Development by Companies, H2 2016 (Contd..2) 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Karyopharm Therapeutics, Inc., H2 2016 22
Pipeline by Stemline Therapeutics, Inc., H2 2016 24
Dormant Projects, H2 2016 51
Dormant Projects (Contd..1), H2 2016 52
Dormant Projects (Contd..2), H2 2016 53
Discontinued Products, H2 2016 54

List of Figures

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Mice Model Market by Type (Inbred, Knockout, Hybrid), Technology (CRISPR, Microinjection), Application (Oncology, Diabetes), Service (Breeding, Quarantine, Genetic testing) & Care Products (Bedding, Feed) - Analysis & Global Forecast to 2021
    Published: 21-Feb-2017        Price: US 5650 Onwards        Pages: 269
    Mice models are indispensable in research activities dealing with human disease processes due to striking similarities between the anatomy, physiology, and genetics of humans and mice. These advantages promote scientific discovery, understanding of the functions of individual genes, mechanisms of different diseases, and the effectiveness and toxicities of various drug molecules. Mice models are the most popularly used animal models due to their small size, short generation time, accelerated l......
  • PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017
    Published: 13-Feb-2017        Price: US 2950 Onwards        Pages: 311
    DelveInsight's, "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors. This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with arou......
  • 3D Bioprinting Market by Technology (Microextrusion, Inkjet, Laser, Magnetic), Material (Cells, Hydrogels, Extracellular Matrices, Biomaterials), Application (Clinical (Bone, Cartilage, Skin) & Research (Regenerative Medicine)) - Global Forecasts to 2021
    Published: 01-Feb-2017        Price: US 5650 Onwards        Pages: 143
    The 3D bioprinting market is expected to reach USD 1,332.6 million by 2021, at a CAGR of 26.5% from 2016 to 2021. The 3D bioprinting market is primarily driven by the rising demand for organ transplantation across the globe. In addition, growing R&D in the field of 3D bioprinting, increasing public and private investments to support 3D bioprinting research, and rising use of 3D bioprinting in drug discovery are supporting the growth of this market. On the other hand, limitations o......
  • United Therapeutics Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand United Therapeutics and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand co......
  • Seattle Genetics Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Seattle Genetics and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand compa......
  • Morphosys Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Morphosys and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand company repo......
  • Gilead Sciences Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Gilead Sciences and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand compan......
  • Genzyme Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Genzyme and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand company report......
  • Genmab Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Genmab and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand company reports......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs